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Abstract
Background: Gram-negative bacterial bloodstream infection (BSI) is a serious condition with estimated 30%
mortality. Clinical outcomes for patients with severe infections improve when antibiotics are appropriately chosen and
given early. The objective of this study was to estimate the association of prior healthcare exposure on time to
appropriate antibiotic therapy in patients with gram-negative BSI.
Method: We performed a multicenter cohort study of adult, hospitalized patients with gram-negative BSI using time
to event analysis in nine community hospitals from 2003-2006. Event time was defined as the first administration of
an antibiotic with in vitro activity against the infecting organism. Healthcare exposure status was categorized as
community-acquired, healthcare-associated, or hospital-acquired. Time to appropriate therapy among groups of
patients with differing healthcare exposure status was assessed using Kaplan-Meier analyses and multivariate Cox
proportional hazards models.
Results: The cohort included 578 patients with gram-negative BSI, including 320 (55%) healthcare-associated, 217
(38%) community-acquired, and 41 (7%) hospital-acquired infections. 529 (92%) patients received an appropriate
antibiotic during their hospitalization. Time to appropriate therapy was significantly different among the groups of
healthcare exposure status (log-rank p=0.02). Time to first antibiotic administration regardless of drug
appropriateness was not different between groups (p=0.3). The unadjusted hazard ratios (HR) (95% confidence
interval) were 0.80 (0.65-0.98) for healthcare-associated and 0.72 (0.63-0.82) for hospital-acquired, relative to
patients with community-acquired BSI. In multivariable analysis, interaction was found between the main effect and
baseline Charlson comorbidity index. When Charlson index was 3, adjusted HRs were 0.66 (0.48-0.92) for
healthcare-associated and 0.57 (0.44-0.75) for hospital-acquired, relative to patients with community-acquired
infections.
Conclusions: Patients with healthcare-associated or hospital-acquired BSI experienced delays in receipt of
appropriate antibiotics for gram-negative BSI compared to patients with community-acquired BSI. This difference was
not due to delayed initiation of antibiotic therapy, but due to the inappropriate choice of antibiotic.
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Introduction
Timely and appropriate antimicrobial therapy is critically
important for treatment of patients with severe infections.
Inadequate timing or choice of antibiotics increases the risk
that patients will die; even a few hours of delay increases
mortality risk in patients with severe infections [1-7]. Multiple
studies examined the detrimental effects of inappropriate
empiric antibiotic therapy on outcomes of death, length of stay,
and hospital costs [1,4,6,8,9]. A meta-analysis of >70 studies,
including non-intensive care populations, demonstrated that
inappropriate empiric antibiotic therapy was associated with a
1.6-fold increase in mortality [1]. These findings have led to
dedicated efforts to minimize the time to administration of
appropriate antibiotics [10].
Although the impact of inappropriate empiric antibiotic
therapy has been well-established, unanswered questions
remain. Specifically, what types of patients are at risk for
delayed appropriate therapy? Antibiotic management of Gram-
negative infections is increasingly difficult due to drug
resistance and lagging antibiotic development [11]. Gram-
negative bloodstream infections carry a mortality rate of 30% or
worse when inappropriate antibiotics are given [7,12]. Risk
factors for delayed appropriate therapy in patients with Gram-
negative bloodstream BSI are not fully understood. Finally, the
majority of US healthcare is delivered in community hospitals;
however antibiotic prescribing practices are rarely studied in
this practice setting [13].
Prior studies have identified patient groups at increased risk
for inappropriate empiric antibiotic therapy, which include
patients with Gram-negative infections or nosocomial
acquisition [2,4,14-18]. However, prior studies have not
critically examined the time to administration of appropriate
antibiotic therapy. Prior investigators used a pre-defined time
point (e.g. 24 hours after blood culture collection) to create a
binary measure of inappropriate empiric antibiotic therapy.
Researchers focused on a short window in time to capture
empiric choices, rather than addressing the larger goal of
administering effective therapy as early as possible.
Consequently, we understand little about how antibiotic
treatment decisions evolve over time in the course of a
patient’s illness.
Time to appropriate antibiotic therapy has recently been
proposed as a quality measure and needs further study [19].
This process-based outcome could be used to evaluate the
quality of antimicrobial management or antimicrobial
stewardship programs [19].
The objective of this multicenter cohort study was to estimate
the effect of healthcare exposure status on the time to receive
appropriate antibiotic therapy in patients with Gram-negative
BSI from the community hospital setting.
Ethics Statement
This study was reviewed and approved by the Institutional
Review Board (IRB) of Duke University Health System.
Participating community hospitals deferred to the Duke IRB
(n=5), or reviewed and approved the study via their local IRB
(n=4). Written patient consent was waived by all sites.
Methods
This retrospective cohort study included patients at nine
community, non-academic hospitals in North Carolina and
Virginia affiliated with the Duke Infection Control Outreach
Network (DICON) [20,21]. The median size of participating
hospitals was 151 (range 102-355) beds.
BSI events were defined using Centers for Disease Control
and Prevention (CDC) criteria for laboratory-confirmed BSI: ≥ 1
positive blood culture for all bacterial pathogens except
common skin contaminants, which required ≥ 2 positive blood
cultures within a 48 hour period [22,23]. The BSI definition was
applied to all blood culture results in participating hospitals’
microbiology databases from January 1, 2003 to December 31,
2006. Data abstractors reviewed charts randomly selected by a
computer-generated list and applied two eligibility criteria: age
≥18 years old, and events occurring during hospitalization or
within one day prior to admission. Data from 1,478 patients
with bloodstream infections were entered into the cohort
database. Clinical, microbiologic, and treatment data were
collected from 24 hours prior to admission through discharge.
Patients with Gram-negative BSI pathogens were selected
from the larger cohort for the current study.
Variable Definitions
Time of BSI event was defined as collection date and time of
first positive blood culture growing the Gram-negative
pathogen. The main outcome was time to receipt of appropriate
antibiotic therapy.
Antibiotic therapy was appropriate if two criteria were met: 1)
the pathogen was susceptible to the antibiotic in vitro, and 2)
antibiotic and route of administration would provide adequate
bioavailability for treatment of BSI. For example, a pathogen
may show in vitro susceptibility to nitrofurantoin; however this
was deemed inappropriate for BSI due to poor antimicrobial
activity in plasma.
Time to appropriate therapy was defined as starting 24 hours
prior to collection of first positive blood culture (“time 0”) and
ending with receipt of first dose of appropriate antibiotic (the
event). Ideally, time 0 starts with the first opportunity for a
clinician to recognize the onset of bacteremia; however, this
was impossible to measure retrospectively. Therefore, we
included appropriate antibiotic choices made during the 24
hours leading up to collection of blood cultures. Although blood
cultures should be collected prior to initiation of antibiotic
therapy, empiric antibiotic therapy before obtaining blood
cultures is a common practice. To be clear, time 0 was defined
as the time of blood culture collection minus 24 hours for the
purposes of this analysis. Thus, the time interval analyzed in
this study included time in the emergency room for patients
presenting from the community. Patients who were receiving
an appropriate antibiotic for >24 hours at the time of blood
culture collection were defined as “breakthrough” BSIs [24].
Breakthrough BSIs were excluded from analysis because
patients had experienced the event prior to start of the risk
period.
Polymicrobial infection was defined as presence of >1
pathogen during any single BSI event. If multiple Gram-
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negative pathogens were present during the same BSI event,
appropriate therapy did not occur until at least one agent active
against each Gram-negative pathogen was administered.
Patients who never received an appropriate antibiotic were
administratively censored at noon on day of discharge or 240
hours (10 days), whichever came first. Patients who received
an appropriate antibiotic >10 days from time 0 were censored
at 240 hours and considered not to have experienced the
outcome. Administrative censoring was utilized to dampen the
skewing effect of the few patients who had a prolonged
admission without appropriate therapy.
Time to any antibiotic therapy, regardless of
appropriateness, was explored as a secondary outcome and
defined similarly. Time 0 started 24 hours prior to collection of
first positive blood culture. Event was receipt of first dose of
any antibiotic without consideration of in vitro activity or
bioavailability. Administrative censoring was the same as
described above.
Healthcare exposure status was the main exposure of
interest, categorized into three groups using a definition
modified from Friedman et al. [25] Healthcare-associated BSI
occurred < 48 hours from admission and patients had ≥1 of the
following healthcare exposure risk factors: 1) presence of an
invasive device or 2) history of prior hospitalization, surgery,
dialysis, or residence in long-term care facility within one year
preceding the BSI event. Community-acquired BSI occurred <
48 hours after admission in patients without healthcare
exposure risk factors. Hospital-onset BSI occurred ≥ 48 hours
after hospital admission.
Multidrug-resistant (MDR) phenotype was defined using
published consensus definitions [26]. Infection source was
defined based on microbiologic and clinical data. If the same
pathogen was isolated from blood and another body site, the
non-blood site was presumed to be the source. If a patient had
a central venous catheter and no matching culture from
another body site, the source was presumed to be the vascular
catheter.
Charlson comorbidity index measured at hospital admission
and APACHE II score measured on day of BSI were calculated
as previously described [27,28].
Statistical Analysis
Descriptive statistics summarized the patient cohort. Kaplan-
Meier curves were constructed for time to appropriate therapy
and time to any antibiotic therapy. Log-rank tests were used to
compare among groups of healthcare exposure status. Alpha
level of 0.05 and two-sided tests were used with any
exceptions noted below.
Cox proportional hazard models were fit to measure the
hazard ratios (HR) and 95% confidence intervals (CI) for the
association between healthcare exposure and time to
appropriate therapy. Proportional hazards assumptions were
tested using time-dependent variables. Clustering due to
hospital-specific factors were accounted for using the methods
of Lee et al. and the robust covariance estimator [29]. Patients
with community-acquired BSI were the referent category.
Indicator variables for healthcare-associated and hospital-
acquired BSI provided separate comparisons to the referent.
Covariates were chosen from factors theorized to impact the
association between healthcare exposure and time to
appropriate therapy. Covariates directly used in definitions of
healthcare exposure (e.g., presence of an invasive device)
were excluded. Charlson index and age were determined a
priori to be important and were included in modeling regardless
of statistical significance.
Selected covariates were evaluated for effect measure
modification using hierarchical models with interaction terms
and likelihood ratio tests (LRT) for model fit (a priori alpha<0.1).
Each covariate deemed not to be a potential modifier was
evaluated individually for association with the main exposure (a
priori alpha<0.05) among all patients, and then the main
outcome among patients in the referent category (a priori
alpha<0.1) to determine potential confounding.
Covariates significant in analyses of interaction or
confounding were included in the initial multivariate model and
then evaluated for removal using a backward elimination
approach. Covariates were removed for the final model based
on two criteria: 1. Model terms for interaction did not improve
model fit by LRT<0.1; 2. Model terms for possible confounders
did not affect the absolute change in HR >10% among any
strata of effect measure modifier or improve model fit by
LRT<0.05 when compared to the initial model.
Two separate multivariate models were constructed. Model 1
was designed to estimate the full association of healthcare
exposure status and did not adjust for intermediate factors that
occur as a result of healthcare exposure: organism type,
polymicrobial infection, MDR, source of infection, and severity
of illness. Intermediate variables were adjusted for, however, in
design of an exploratory Model 2 to estimate the direct
association between healthcare exposure and time to
appropriate therapy.
All analyses were completed using SAS Version 9.3.1 (Cary,
North Carolina).
Results
Description of Study Cohort
The study cohort included 578 patients with Gram-negative
BSIs after removal of 19 patients with breakthrough BSI. A total
of 320 (55%) patients had healthcare-associated, 217 (38%)
had community-acquired, and 41 (7%) had hospital-acquired
BSI (Table 1). Most patients were elderly (median age 72
[range 18-97]). The majority were on Medicare or Medicaid
(81%). Over half (56%) had impairment in at least one activity
of daily living.
A total of 598 Gram-negative pathogens were isolated from
578 patients (Table 2). Forty-eight (8%) BSIs were
polymicrobial; 18 (3%) involved more than one Gram-negative
pathogen. The predominant pathogens were
Enterobacteriaceae. E. coli was observed more commonly in
community-acquired BSI, whereas Enterobacter was
predominately found in hospital-acquired BSI.
MDR phenotype was observed in 84 (15%) patients in the
entire cohort. MDR was more common in healthcare-
associated (n=58, 18%) and hospital-acquired (n=6, 13%)
BSIs, than in community-acquired BSIs (n=10, 9%) (Table 1).
Appropriate Therapy for Gram-Negative BSI
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Table 1. Characteristics of Patients by Healthcare Exposure Status.















 72 (18-97) 69 (18-97) 73.5 (19-97) 73 (36-94) 0.01
 Male Sex  257 (44) 85 (39) 146 (46) 26 (63) 0.01
 Non-white Race  266 (47) 87 (40) 164 (52) 15 (34) 0.02
 Medicare/Medicaid  463 (81) 158 (74) 267 (85) 38 (83) <.001
 No insurance  31 (5) 18 (8) 12 (4) 1 (2) 0.06








 14 (4-30) 13 (4-28) 15 (4-30) 14 (7-29) 0.006
 MCCabe score b      <.001
  Rapidly fatal <2 weeks 105 (19) 35 (17) 56 (18) 14 (35)  
  Ultimately fatal <5 years 302 (52) 82 (39) 199 (62) 21 (51)  
  Nonfatal 159 (28) 95 (45) 59 (18) 5 (12)  
 Dependent in ≥1 ADL b  323 (56) 91 (42) 208 (65) 24 (59) <.001
 Dependent in ≥3 ADL b  136 (24) 24 (11) 107 (34) 5 (11) <.001
 Admission source b Home 440 (75) 211 (100) 201 (64) 28 (61) d
  Skilled nursing facility 121 (21) 0 (0) 114 (36) 7 (15)  
  Other hospital 6 (1) 0 (0) 0 (0) 6 (13)  
 
Prior hospitalization in
last 1 year b
 251 (43) 0 (0) 232 (73) 19 (41) d
 Comorbidities b Diabetes 220 (38) 70 (32) 147 (46) 8 (17) <.001
  MI 118 (20) 40 (18) 63 (20) 15 (33) 0.03
  CHF 109 (19) 29 (13) 68 (21) 12 (26) 0.02
  PVD 77 (13) 26 (12) 44 (14) 7 (15) 0.6
  Stroke 112 (19) 21 (10) 86 (27) 5 (5) <.001
  Dementia 102 (18) 21 (10) 78 (24) 3 (7) <.001
  COPD 100 (17) 31 (14) 58 (18) 11 (24) 0.1
  Liver disease 36 (6) 15 (7) 17 (5) 4 (9) 0.6
  Dialysis 35 (6) 0 (0) 32 (10) 3 (7) d
  Active Malignancy 127 (22) 36 (17) 80 (25) 11 (24) 0.05
  Metastatic Malignancy 26 (4) 6 (3) 16 (5) 4 (9) 0.09
  Decubitus ulcer 79 (14) 11 (5) 62 (19) 6 (13) <.001
  Immunosuppression 56 (10) 21 (10) 31 (10) 4 (9) 0.99
 Devices b Central IV catheter 61 (10) 0 (0) 47 (15) 14 (30) d
  Foley catheter 64 (11) 0 (0) 61 (19) 3 (7) d
  PEG 28 (5) 0 (0) 23 (7) 5 (11) d
Infection
Characteristics
Polymicrobial  48 (8) 10 (5) 30 (9) 8 (17) 0.004
 Multiple GN pathogens  18 (3) 4 (2) 10 (3) 4 (9) 0.1
 Multidrug Resistance  84 (15) 20 (9) 58 (18) 6 (13) 0.02
 Primary Source      0.008
  Urine 96 (17) 42 (19) 48 (15) 6 (15)  
  Wound 4 (1) 2 (1) 2 (1) 0 (0)  
  Lower respiratory tract 8 (1) 2 (1) 3 (1) 3 (7)  
  Other  9 (2) 3 (1) 2 (1) 4 (10)  
  No culture or unknown 406 (70) 168 (77) 223 (70) 15 (37)  






 26.9 25.9 27.9 27.3 0.02
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Seventy percent of patients had no identified source for their
BSI. The remaining patients had a matching culture from an
alternate body site (n=117, 20%) or were presumed to have a
central line-associated infection (n=55, 10%).
A total of 1,648 courses of antibiotics were administered to
study patients during their admission (mean 2.2, standard
deviation 1.3 per patient). The most common antibiotics
administered were ceftriaxone (n=294, 18%), levofloxacin
Table 1 (continued).









   (26.2, 28.3) (25.4, 27.7) (26.6, 28.9) (25.3, 48.0)  
 
Time to any antibiotic
therapy, hours, median
(95% CI)
 26.4 25.8 27.2 26.4 0.3
   (25.8, 27.5) (25.2, 26.8) (26.1 28.2) (25.0, 36.8)  
 Disposition Death or hospice 82 (14) 17 (8) 53 (17) 12 (29) <.001
  
Discharge to skilled nursing
facility
193 (34) 18 (8) 102 (32) 9 (22) <.001
  
Discharge home with home
health services
42 (7) 10 (5) 28 (9) 4 (10) 0.2
 ICU admission  151 (26) 65 (30) 70 (22) 16 (40) 0.02
 Intubation  55 (10) 19 (9) 27 (9) 9 (22) 0.02
 Vasopressors  66 (12) 26 (12) 32 (10) 8 (21) 0.3
 Readmission in 90 days  143 (25) 42 (20) 93 (29) 8 (20) <.001
 
Length of stay post BSI,
days, median (range)
 6 (0-158) 5 (0-158) 6 (0-143) 7 (0-52) 0.3
Note: Data are number (%) of bloodstream infection events unless otherwise indicated.
BMI = body mass index; APACHE II = Acute Physiology and Chronic Health Evaluation II score; ADL = activity of daily living; MI = myocardial infarction; CHF = congestive
heart failure; PVD = peripheral vascular disease; COPD = chronic obstructive pulmonary disease; IV = intravenous; PEG = percutaneous endoscopic gastrostomy; GN =
gram negative; CI = confidence interval; ICU = intensive care unit; BSI = bloodstream infection.
a. Sums may not equal total N due to small numbers of missing data (not shown) which were less than 10% for any single variable and distributed evenly among groups of
healthcare exposure.
b. Measured on admission.
c. Measured on day of bloodstream infection.
d. Significance testing not performed on variables directly used in definitions of healthcare exposure groups.
e. P values indicate chi-squared or Fisher exact tests for categorical variables, or ANOVA or Kruskall-Wallis tests for continuous variables, as appropriate. All tests were two-
sided, using two degrees of freedom. Time to appropriate therapy and time to first therapy were assessed using log-rank tests.
doi: 10.1371/journal.pone.0076225.t001
Table 2. Distribution of Gram-negative Bloodstream Infection Pathogens.
 Total Cohort (N =598)a Community-associated (n=221) Healthcare-associated (n=331) Hospital-acquired (n=46)
E. coli 330 (55) 148 (67) 167 (50) 15 (33)
Klebsiella 91 (15) 42 (19) 42 (13) 7 (15)
Proteus 53 (9) 7 (3) 40 (12) 6 (13)
Pseudomonas 43 (7) 9 (4) 31 (9) 3 (7)
Enterobacter 30 (5) 3 (1) 15 (5) 12 (26)
Acinetobacter 10 (2) 1 (0) 9 (3) 0 (0)
Citrobacter 9 (2) 1 (0) 7 (2)  1 (0)
Serratia 9 (2) 3 (1) 6 (2) 0 (0)
Salmonella 7 (1) 2 (1) 5 (2) 0 (0)
Otherb 16 (3) 5 (2) 9 (3) 2 (4)
Note: Data are number (%) of isolates unless otherwise indicated.
a. 598 pathogens were isolated from 578 patients. 18 patients had >1 Gram-negative pathogen isolated.
b. Other organism types include Morganella, Providencia, Stenotrophomonas, Pasteurella, Alcaligenes. All had frequencies of <5 (1%) of bloodstream infection events.
doi: 10.1371/journal.pone.0076225.t002
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(n=207, 13%), ciprofloxacin (n=189, 12%), and piperacillin-
tazobactam (n=149, 9%).
We observed significant differences in secondary outcomes,
including mortality, discharge to skilled nursing facility,
intubation, and readmission in 90 days among the three groups
of healthcare exposure status (Table 1).
Kaplan-Meier Analysis
Five hundred twenty-nine (92%) of 578 patients received
appropriate therapy during the 10-day risk period. Forty-nine
(8%) patients were administratively censored at discharge or
day 10. Time to appropriate therapy was significantly different
for the three groups (log-rank p=0.02, Figure 1A). Unadjusted
analysis revealed median (95% CI) time to appropriate therapy
of 25.9 (25.4, 27.7) hours among community-acquired, 27.9
(26.7, 28.9) hours among healthcare-associated, and 27.3
(25.3, 48.0) hours among hospital-acquired patients. Larger
differences in time to appropriate therapy for each healthcare
exposure group were seen after the first 24 hour time period or
for the latter two quartiles of patients. For example, 75% of
patients with community-acquired infections had received an
appropriate antibiotic by 36.6 (32.9-43.4) hours. In contrast, it
took 47.4 (42.8-63.6) hours for 75% of the healthcare-
associated, and 51.3 (43.6-99.5) hours for 75% of the hospital-
acquired groups to receive appropriate therapy.
All study patients received at least one antibiotic in the 10
days following BSI. The time to any antibiotic therapy,
regardless of effectiveness, was not significantly different
Figure 1.  Cumulative hazard of receiving appropriate antibiotic therapy or any antibiotic therapy based on Kaplan-Meier
analysis.  Cumulative hazards among healthcare exposure categories of patients with Gram-negative bloodstream infections in
community hospitals, 2003-2006. Healthcare exposure categories include community-acquired (dashed dark-gray line), healthcare-
associated (solid light-gray line), and hospital-acquired (dotted light-gray line). For all analyses, the origin of the risk period was
defined as starting 24 hours prior to blood culture collection.
A. The cumulative hazard of receiving the first dose of an appropriate antibiotic, log-rank test p=0.02.
B. The cumulative hazard of receiving the first dose of any antibiotic, log-rank test p=0.3.
doi: 10.1371/journal.pone.0076225.g001
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among the three groups of healthcare exposure status (log-
rank p=0.3) (Figure 1B).
Multivariate Analysis
Unadjusted Cox analysis suggested that patients with
healthcare-associated (HR 0.80, 95% CI 0.65-0.98, p=0.03) or
hospital-acquired (HR 0.72, 95% CI 0.63-0.82, p=<.001) BSI
experienced delays in receiving appropriate therapy when
compared to patients with community-acquired BSI. Tests for
violation of the proportional hazards assumption were not
significant.
Charlson score, body mass index, and active malignancy
were found to be potential effect measure modifiers. We
pursued a single interaction only due to lack of power to
evaluate multivariable interactions. Therefore, only interaction
terms between Charlson and the main exposure were included
in subsequent modeling.
Exclusion of variables based on a priori criteria reduced the
covariate pool to Charlson, age, body mass index, male sex,
Medicare/Medicaid, active malignancy, non-white race, and
functional status. Following backward elimination, the final
adjusted Model 1 included the main exposure, Charlson plus
interaction terms, age, active malignancy, Medicare/Medicaid,
and dependence in ≥ 3 activities of daily living. Final adjusted
HR (aHR) estimates among strata of Charlson revealed that
healthcare-associated and hospital-onset infections were
associated with delay in receipt of appropriate antibiotic
therapy compared with community-acquired infections (Table
3, Model 1, Figure 2). The effects were strongest among
patients with lower Charlson index and hospital-acquired BSI
(aHR 0.41, 95% CI 0.26-0.65). The aHR became weaker and
included the null in the strata of higher Charlson index among
patients with hospital-acquired BSI (aHR 0.90, 95% CI
0.46-1.77).
Model 2 also included adjustment for intermediate causal
factors: organism type, polymicrobial infection, MDR, source of
infection, and APACHE II score. Individual stratums’ aHR
estimates generally remained significantly different from, but
slightly closer to, the null when compared to Model 1 (Table 3,
Model 2). In other words, patients with healthcare exposures
demonstrated delayed time to appropriate therapy despite
adjustment for potentially explanatory factors like MDR,
polymicrobial infection, organism type, and source of infection.
Discussion
This multicenter study from the community hospital setting
demonstrated that patients with healthcare-associated or
hospital-acquired Gram-negative BSI experienced delay in
receipt of appropriate antibiotics when compared to patients
with community-acquired BSI. Studies that previously
examined the effect of healthcare exposures on inappropriate
empiric antibiotic therapy generally did not use a time to event
analysis [4,8,14,15,18,30,31]. Also, the patient cohort included
community hospital patients with Gram-negative BSI which is
an understudied population in existing research examining
inappropriate antibiotic therapy.
The time to appropriate therapy was significantly different
among community-acquired, healthcare-associated, and
hospital-acquired patients in unadjusted analysis. In contrast,
time to receipt of the first dose of any antibiotic, regardless of
appropriateness, was not significantly different among the
patient groups. This suggests that reasons for the delay were
not due to the logistics of administering antibiotics, failure to
recognize a need for antibiotics, or decisions not to treat, but
due to selection of an inappropriate antibiotic. The association
persisted in multivariate analyses despite adjustment for
confounders as well as explanatory intermediate factors, like
MDR and organism type. Thus, a higher rate of drug-resistance
only partially explains our observation of delayed appropriate
therapy in healthcare-exposed patients.
Table 3. Effect of Healthcare Exposure on Time to Appropriate Antibiotic Therapy.
Charlson score Healthcare Exposure Status Adjusted Hazard Ratio (95% CI)
  Model 1a Model 2b
Charlson score=0 Community-acquired 1 1
 Healthcare-associated 0.56 (0.33-0.95) 0.60 (0.34-1.05)
 Hospital-acquired 0.41 (0.26-0.65) 0.51 (0.32-0.80)
Charlson score=3 Community-acquired 1 1
 Healthcare-associated 0.66 (0.48-0.92) 0.64 (0.46-0.89)
 Hospital-acquired 0.57 (0.44-0.75) 0.65 (0.49-0.85)
Charlson score=7 Community-acquired 1 1
 Healthcare-associated 0.82 (0.70-0.98) 0.71 (0.60-0.85)
 Hospital-acquired 0.90 (0.46-1.77) 0.90 (0.50-1.62)
Note: 566 patients were included in the multivariate analyses due to small amounts (2%) of missing data distributed among the covariates used for adjustment.
a. Adjusted for the following covariates: Charlson index plus interaction terms, age, Medicare/Medicaid, Dependent in >3 activities of daily living
b. Adjusted for the following covariates: Charlson index plus interaction terms, age, Medicare/Medicaid, Dependent in >=3 activities of daily living, polymicrobial infection,
organism type (monomicrobial infections with E. coli, Klebsiella, Non-fermenter, other Enterobacteriaceae, other); multidrug-resistance; primary source type; APACHE II
score at the time of bloodstream infection.
doi: 10.1371/journal.pone.0076225.t003
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We theorize that a higher degree of clinical uncertainty
involved in evaluation of patients with healthcare exposures
may explain these findings. When choosing empiric therapy,
clinicians must assess an individual’s epidemiologic risk factors
and search for a primary infection. However, practicing
clinicians are often faced with complicated, confusing, and
sometimes mysterious clinical presentations. For example,
hospitalized patients may develop acute complications during
their inpatient stay (e.g., drug reaction, delirium) that make
clinical evaluation more challenging. These healthcare-related
events were not captured in our study.
Time of initial clinical evaluation may also impact the degree
of clinical uncertainty. Community-acquired patients who
present for care several days after infection onset may have
clear manifestations of their primary source. In contrast,
healthcare-exposed patients may be evaluated early in their
infection course and lack symptoms of a localized source. Early
access to care could affect disease latency at the time of first
clinical evaluation and thus impact the ease of diagnosis and
antibiotic choice.
We found evidence of interaction with baseline comorbidity
and the association between healthcare exposure and time to
appropriate therapy. The hazard ratio appeared strongest when
Charlson index was low, which may be related to lack of
statistical power when Charlson was high. Alternatively, more
appropriate (or aggressive) antibiotic therapy may have
occurred in patients with high baseline comorbidity. We cannot,
however, make this conclusion with our data.
Definition of the time component for appropriate antibiotic
therapy is not standardized. Most prior studies have examined
inappropriate empiric therapy, defined as the lack of receipt of
an effective antibiotic within 24 hours from blood culture
collection, or in the 48 hour period surrounding blood culture
collection (e.g. 1 day before to 1 day after) [3,18,32]. In the few
studies that have used time to appropriate therapy, the time
period prior to blood culture collection was generally not
discussed [32-34]. These studies were also limited to specific
Figure 2.  Probability of remaining on inappropriate antibiotic therapy based on Cox proportional hazards
model.  Healthcare exposure categories include community-acquired (dashed dark-gray line), healthcare-associated (solid light-
gray line), and hospital-acquired (dotted light-gray line). Model inputs to produce these curves were the following: Charlson index of
0, malignancy=none, age >65, Medicare/Medicaid=yes, dependent in >3 activities of daily living=yes.
doi: 10.1371/journal.pone.0076225.g002
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pathogens. Using Kaplan-Meier analysis, we discretely
observed how appropriate antibiotics were administered from
24 hours before blood culture collection up to 10 days later
(Figure 1). Importantly, 25% of patients received appropriate
therapy before collection of blood cultures. Exclusion of this
group in previous studies may have resulted in over-
representation of patients with delayed therapy. Further, this
suboptimal culture collection practice impairs ascertainment of
bacteremic patients.
This study is limited by its retrospective design, which may
have resulted in measurement error or uncontrolled
confounding. Limited data could be gathered regarding a
primary source of BSI, and the true timing of blood culture
collection as compared to the documented date and time could
not be validated. Also, unmeasured or unknown confounding
factors could have affected the multivariate analysis. Second,
the study period 2003-2006 may not reflect current antibiotic
prescribing practices or prevalence of multidrug resistance.
Third, we did not examine antibiotic dose, which is important
for optimal antibiotic therapy. We believe, however, that this
study has relevance for today’s prescribers. It highlights the
need to assess healthcare-associated risk factors and provides
greater understanding of effects of prior healthcare exposure
on treatment decisions.
Early, effective antibiotic therapy is important for providing
high quality care for patients with Gram-negative BSI. We
demonstrated that healthcare-exposed patients are at risk for
delayed receipt of appropriate antibiotics.
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